Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Clavamox vs Augmentin in Healthy Volunteers
NCT03616301Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amoxicillin and clavulanic acid in bacterial infection, sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration (Cmax) of Amoxicillin, Area Under the Curve to the Last Quantifiable Concentration (AUC0-t) of Amoxicillin and 2 more. Started Jul 2018; status: completed.
02
Drugs
amoxicillinclavulanic acid
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03616301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616301.